Omeros obtained the FDA's approval to initiate a midstage trial of its monoclonal antibody candidate OMS721 in patients with complement-mediated thrombotic microangiopathies. The trial, which will test the safety and efficacy of the drug, is scheduled to start this quarter.
FDA permits trial of Omeros drug for thrombotic microangiopathies
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||